First page Back Continue Last page Image
Proven Durability
through 6 Month Open-Label Follow-up
- Long Term Follow Up After Acute Treatment
- Safety confirmed during long term, open-label 6 month follow up period
- During open-label follow up on antidepressant medication monotherapy,~ 37% of patients required TMS reintroduction
- ~85% of patients who received TMS reintroduction benefited
- Net incidence of illness relapse under these open-label follow up conditions: 11%
- Six-month relapse with antidepressant treatment alone in STAR*D study was
50-65% (Level 2 and 3 range)
- Janicak, et al. Brain Stimulation, 2010.